Theratechnologies Reveals Risk Of Temporary Supply Disruption For EGRIFTA SV In Early 2025 Caused By An Unexpected Voluntary Shutdown Of Contract Manufacturer's Facility Following FDA Inspection
Portfolio Pulse from Benzinga Newsdesk
Theratechnologies announced a potential temporary supply disruption for EGRIFTA SV in early 2025 due to a voluntary shutdown of a contract manufacturer's facility after an FDA inspection. The company plans to manage inventory to meet demand but expects a $1.6 million revenue shortfall for fiscal year 2024.
September 17, 2024 | 9:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Theratechnologies is facing a potential supply disruption for EGRIFTA SV in early 2025 due to a contract manufacturer's shutdown following an FDA inspection. The company plans to manage inventory but anticipates a $1.6 million revenue shortfall for fiscal year 2024.
The news of a potential supply disruption for EGRIFTA SV due to a manufacturer's shutdown is significant for Theratechnologies. The company expects a $1.6 million revenue shortfall for fiscal year 2024, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100